Financials Bio-Works Technologies AB

Equities

BIOWKS

SE0007387089

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Stockholm 16:15:06 29/04/2024 BST 5-day change 1st Jan Change
2.94 SEK 0.00% Intraday chart for Bio-Works Technologies AB +1.38% -58.59%

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 190.3 176.7 243.9 276.8 959 736.4
Enterprise Value (EV) 1 101 122.7 167.5 243.7 856.3 670.6
P/E ratio -8.07 x -4.64 x -5.76 x -6.15 x -66.3 x -16.4 x
Yield - - - - - -
Capitalization / Revenue 29.6 x 26.9 x 43.8 x 38.3 x 17 x 17.8 x
EV / Revenue 15.7 x 18.7 x 30.1 x 33.7 x 15.2 x 16.2 x
EV / EBITDA -4.6 x -3.86 x -4.01 x -5.36 x -81.8 x -14.4 x
EV / FCF -7.04 x -5.31 x -6.58 x -8.96 x -104 x -26.3 x
FCF Yield -14.2% -18.8% -15.2% -11.2% -0.96% -3.81%
Price to Book 1.92 x 2.87 x 2.97 x 7.39 x 8.84 x 10.9 x
Nbr of stocks (in thousands) 19,316 19,336 30,416 30,416 34,874 35,069
Reference price 2 9.850 9.140 8.020 9.100 27.50 21.00
Announcement Date 24/04/18 26/04/19 28/04/21 28/04/21 27/04/22 28/04/23
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 6.418 6.563 5.572 7.234 56.36 41.32
EBITDA 1 -21.96 -31.81 -41.75 -45.5 -10.47 -46.67
EBIT 1 -23.58 -33.51 -42.13 -45.65 -10.96 -47.14
Operating Margin -367.42% -510.56% -756.07% -631.1% -19.44% -114.09%
Earnings before Tax (EBT) 1 -23.66 -37.96 -42.11 -45.02 -9.37 -44.7
Net income 1 -23.66 -37.96 -42.11 -45.02 -12.94 -44.95
Net margin -368.6% -578.32% -755.8% -622.33% -22.96% -108.79%
EPS 2 -1.220 -1.970 -1.392 -1.480 -0.4147 -1.284
Free Cash Flow 1 -14.34 -23.09 -25.46 -27.21 -8.227 -25.53
FCF margin -223.47% -351.83% -456.93% -376.1% -14.6% -61.79%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 24/04/18 26/04/19 28/04/21 28/04/21 27/04/22 28/04/23
1SEK in Million2SEK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S2 2021 S1 2022 S1 2022 S2
Net sales 1 3.541 8.288 - 23.18
EBITDA 1 - 9.6 - -22.04
EBIT 1 - 9.256 - -22.31
Operating Margin - 111.68% - -96.25%
Earnings before Tax (EBT) 1 - - - -21.36
Net income 1 - - -23.53 -21.49
Net margin - - - -92.75%
EPS -0.7900 - -0.6700 -
Dividend per Share - - - -
Announcement Date 19/02/21 20/08/21 19/08/22 17/02/23
1SEK in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 - - - - - -
Net Cash position 1 89.2 54.1 76.4 33.1 103 65.9
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -14.3 -23.1 -25.5 -27.2 -8.23 -25.5
ROE (net income / shareholders' equity) -38.5% -47.2% -58.6% -75.3% -17.7% -51%
ROA (Net income/ Total Assets) -22.1% -24.3% -33.9% -42.7% -8.23% -27.7%
Assets 1 107 156.5 124.3 105.3 157.2 162.1
Book Value Per Share 2 5.140 3.190 2.700 1.230 3.110 1.930
Cash Flow per Share 2 4.620 2.800 2.510 1.090 2.950 1.870
Capex 1 0.56 0.78 0.22 0.33 0.94 1.12
Capex / Sales 8.66% 11.9% 3.95% 4.51% 1.67% 2.72%
Announcement Date 24/04/18 26/04/19 28/04/21 28/04/21 27/04/22 28/04/23
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. BIOWKS Stock
  4. Financials Bio-Works Technologies AB